Please ensure Javascript is enabled for purposes of website accessibility

What Are Investors Thinking About Fulgent Genetics?

By Keith Speights and Brian Orelli, PhD - May 14, 2021 at 7:10AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Hint: It has something to do with COVID-19.

Fulgent Genetics (FLGT -11.93%) recently announced impressive first-quarter results. However, its stock remains well below the highs set earlier this year. In this Motley Fool Live video recorded on May 5, Motley Fool contributors Keith Speights and Brian Orelli answer a viewer's question about what investors are thinking these days about Fulgent.

Keith Speights: Will asks, "Can you guys please shed some wisdom on Fulgent Genetics?" FLGT is the ticker there. Will says, "The amount of cash they have is mind-blowing and the amount if sell-off is also mind-blowing. Their CEO is probably top one percent of CEOs in my opinion and I know they have a lot of COVID income. What in the world are investors thinking?"

So Brian, what in the world are investors thinking about Fulgent?

Brian Orelli: Investors are thinking that the COVID-19 testing is going way down, because there was so much of the growth story in the last year, that growth story will go away.

So we had talked previously about Exact Sciences, looking at $32.3 million in sales in the first quarter and only expecting $50 to $60 million for all of 2021. So that means they've done as much in the first quarter that they're going to expect in the next three quarters or less.

So I think that the issue is just that it's really hard to value a company when you don't understand their growth prospects in multiple years out. I don't think anybody really knows what the number of COVID-19 tests that are going to be required in 2022, 2023, or even in the fourth quarter of 2021.

So I think that the only way to do it is just based on the current situation and so that's what people have been doing and that's been causing the roller coaster ride that's caused Fulgent to go super high. Then now has crashed back down and where it will end up will probably be dependent more on the company's other genetic tests than they were with the COVID-19 tests.

Brian Orelli, PhD has no position in any of the stocks mentioned. Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Fulgent Genetics, Inc. The Motley Fool recommends Exact Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Fulgent Genetics, Inc. Stock Quote
Fulgent Genetics, Inc.
$52.72 (-11.93%) $-7.14
Exact Sciences Corporation Stock Quote
Exact Sciences Corporation
$46.81 (-0.51%) $0.24

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/09/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.